SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development, data storage, will participate in the virtual SRC-SIA Webinar on the Decadal Plan for Semiconductors held on December 9, 2021 from 12:30pm to 2:00pm (EST). The webinar aims to identify a compelling research agenda based on the Decadal Plan for Semiconductors to discover new approaches to memory and storage. Mr. Hellmold will participate as a panelist in the roundtable discussion titled “New Trajectories for Memory and Storage.” To register for the webinar visit: https://www.semiconductors.org/events/src-sia-webinardecadal-plan-for-semiconductors-new-trajectories-for-memory-and-storage/.
Current data storage technologies have limited longevity and require frequent data migration for long-term data storage. Given current trajectories for data creation as well as data storage demand, experts estimate that the supply of data storage won’t keep up with demand, concluding that new breeds of storage technologies must be created. This is reflected in the SRC Decadal Plan that includes a goal to discover storage technologies with more than 100 times the current storage density capability along with new storage systems that can leverage these new technologies. DNA Data Storage is the ideal candidate technology to achieve the scaling goals providing a cost-effective, sustainable, and energy-efficient solution for long-term data storage.
When properly stored, DNA provides a stable medium that is durable for thousands of years. Importantly, DNA is expected to enable 100,000 times higher density storage solutions compared to the most advanced tape products. Digital data stored in DNA can be stored in a variety of containers including capsules, pellets or encased in glass beads.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to statements relating to the future demand for data storage and the commercial viability of DNA for long-term data storage, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report Form 10-K filed with the Securities and Exchange Commission on November 23, 2021, and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
